Allergan receives warning letter from FDA

NEW YORK Allergan on Sept. 10 received a warning letter from the Food and Drug Administration around its online promotion of its prescription eyelash thickener/glaucoma treatment Latisse, according to published reports.

According to the letter, FDA believes the Web site for Latisse is misleading because it does not include all of the risk information found in its Drug Information paper.

Allergan was asked to respond by Sept. 24.